CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025
21. Januar 2025 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance
13. Januar 2025 08:00 ET
|
CVRx, Inc.
Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30%Fiscal 2025...
CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
23. Dezember 2024 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Dec. 23, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the 43rd Annual...
CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference
20. November 2024 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 20, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the Piper...
CVRx Announces Positive Outpatient Payment for Barostim Procedure in 2025
04. November 2024 08:00 ET
|
CVRx, Inc.
MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services...
CVRx Reports Third Quarter 2024 Financial and Operating Results
29. Oktober 2024 16:05 ET
|
CVRx, Inc.
MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx announces new CPT® Category I codes for Barostim
18. Oktober 2024 14:08 ET
|
CVRx, Inc.
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT®...
CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
15. Oktober 2024 16:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an...
CVRx announces new publication reinforcing the long-term quality of life benefits of Barostim
12. September 2024 08:00 ET
|
CVRx, Inc.
New data published in JACC: Heart Failure demonstrate durable benefits in MLWHF and EQ-5D quality of life measures in heart failure patients with reduced ejection fraction MINNEAPOLIS, Sept. 12,...
CVRx Announces Appointment of Two New Board Members
03. September 2024 08:30 ET
|
CVRx, Inc.
MINNEAPOLIS, Sept. 03, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced the appointments of Kevin Ballinger and Mitch Hill to...